Difference between revisions of "Blastic plasmacytoid dendritic cell neoplasm"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 10: | Line 10: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=All lines of therapy= | =All lines of therapy= | ||
==Tagraxofusp monotherapy {{#subobject:2471cc|Regimen=1}}== | ==Tagraxofusp monotherapy {{#subobject:2471cc|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:8044|Variant=1}}=== | ===Regimen {{#subobject:8044|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
| Line 29: | Line 28: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Tagraxofusp (Elzonris)]] 12 mcg/kg IV over 15 minutes once per day on days 1 to 5 | *[[Tagraxofusp (Elzonris)]] 12 mcg/kg IV over 15 minutes once per day on days 1 to 5 | ||
| − | |||
'''21-day cycles''' | '''21-day cycles''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''STU 012013-061:''' Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/3/385.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260361/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24859366 PubMed] NCT00397579 | # '''STU 012013-061:''' Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/3/385.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260361/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24859366 PubMed] NCT00397579 | ||
# '''STML-401-0114:''' Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. [https://doi.org/10.1056/NEJMoa1815105 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31018069 PubMed] NCT02113982 | # '''STML-401-0114:''' Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. [https://doi.org/10.1056/NEJMoa1815105 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31018069 PubMed] NCT02113982 | ||
##'''Update:''' Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. [https://doi.org/10.1200/jco.22.00034 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9462530/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35820082/ PubMed] | ##'''Update:''' Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. [https://doi.org/10.1200/jco.22.00034 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9462530/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35820082/ PubMed] | ||
| − | |||
[[Category:Blastic plasmacytoid dendritic cell neoplasm regimens]] | [[Category:Blastic plasmacytoid dendritic cell neoplasm regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Acute leukemias]] | [[Category:Acute leukemias]] | ||
Revision as of 13:15, 28 February 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tagraxofusp monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Frankel et al. 2014 (STU 012013-061) | 2013-NR | Phase 1/2, <20 pts |
| Pemmaraju et al. 2019 (STML-401-0114) | 2014-2017 | Phase 1/2 (RT) |
Targeted therapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed NCT00397579
- STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains dosing details in manuscript PubMed NCT02113982
- Update: Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. link to original article link to PMC article PubMed